INBRAIN gets FDA breakthrough nod for Intelligent Network Modulation System
The FDA’s BDD covers the graphene-neural platform as an adjunctive therapy for Parkinson’s disease by combining machine learning…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Sep 23
The FDA’s BDD covers the graphene-neural platform as an adjunctive therapy for Parkinson’s disease by combining machine learning…
19 Sep 23
The study, published in the preprint server medrxiv, showed that the implant can offer safe and effective brain…
14 Sep 23
A world first, CERVAI on track for commercialization in Q4-2023
06 Sep 23
The company recruited six patients in the COMMAND trial, the US FDA investigational device exemption (IDE) study designed…
06 Sep 23
Axoguard HA+ Nerve Protector is a proprietary nerve protection device uniquely designed to provide both short- and long-term…
05 Sep 23
According to Tyndall National Institute, vagus nerve stimulation uses pacemaker-like electrical current pulses to reduce and stop epileptic…
05 Sep 23
ATLATL streamlines the elements of R&D to improve resource utilization and revolutionizes the traditional asset-heavy investment model into…
30 Aug 23
This marks the first use of the VASCADE system portfolio, widely used in U.S. hospitals, in a European…
29 Aug 23
The RECOVER-NEURO trial is intended to look at accessible interventions for cognitive dysfunction associated with Covid, such as…
22 Aug 23
ArtiFascia is a resorbable dural repair graft that combines two layers of electrospun nanofibers, which promotes dural tissue…